FHTX — Foghorn Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$5.60
-$0.09 (-1.58%)
Foghorn Therapeutics Inc (FHTX) is a biotechnology company listed on NASDAQ. It is led by Adrian H. B. Gottschalk, based in 99 Coolidge Avenue, Watertown, MA, United States, 02472, with about 106 employees. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Latest reported FHTX revenue for 2025-09-30 was $8.2M. Net income was -$15.8M. Revenue was up 7.9% from 2025-06-30 to 2025-09-30. FHTX currently screens at market cap $237.8M.
Use this FHTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the FHTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the FHTX SEC filings page. Lician reads the product cache first so this HTML stays unique to Foghorn Therapeutics Inc even when a live quote feed is slow.
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
FHTX Key Statistics
Market Cap
$237.79M
Volume
402,911
Previous Close
$7.07
Day Range
$6.57 – $7.35
P/B Ratio
2005.35
EPS
-$1.58
Revenue
$22.60M
Net Income
-$86.62M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-33.8%
Profit Margin
-383.2%
Employees
106
FHTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $22.60M | $34.16M | $19.23M | $1.32M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$86.62M | -$98.43M | -$108.88M | -$101.32M |
| EPS (Diluted) | -$1.58 | -$2.34 | -$2.62 | -$2.73 |
Total Assets
$283.98M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$55.45M
Operating Cash Flow
-$100.41M
Free Cash Flow
$0.00
Foghorn Therapeutics Inc Company Information
- President, CEO & Director
- Adrian H. B. Gottschalk
- Headquarters
- 99 Coolidge Avenue, Watertown, MA, United States, 02472
- Website
- foghorntx.com
- Phone
- 617 586 3100
- IPO / Founded
- 2020-10-23
- Sector
- Healthcare
- Industry
- Biotechnology